95 related articles for article (PubMed ID: 15448746)
1. Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
Jazowiecka-Rakus J; Szala S
Acta Biochim Pol; 2004; 51(3):851-6. PubMed ID: 15448746
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma.
Yi C; Huang Y; Guo ZY; Wang SR
Acta Pharmacol Sin; 2005 May; 26(5):629-34. PubMed ID: 15842785
[TBL] [Abstract][Full Text] [Related]
4. [Antitumor efficacy of CD/5-FC suicide gene therapy system mediated by Bifidobacterium infantis against melanoma].
Yi C; Guo ZY; Huang Y; Wang HY; Wang SR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):165-8. PubMed ID: 15807256
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy of B16(F10) murine melanoma using E. coli cytosine deaminase gene and murine interleukin-4 gene.
Missol-Kolka E; Sochanik A; Szala S
Neoplasma; 1998; 45(5):305-11. PubMed ID: 9921920
[TBL] [Abstract][Full Text] [Related]
6. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium.
Mei S; Theys J; Landuyt W; Anne J; Lambin P
Anticancer Res; 2002; 22(6A):3261-6. PubMed ID: 12530073
[TBL] [Abstract][Full Text] [Related]
7. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Nemunaitis J; Cunningham C; Senzer N; Kuhn J; Cramm J; Litz C; Cavagnolo R; Cahill A; Clairmont C; Sznol M
Cancer Gene Ther; 2003 Oct; 10(10):737-44. PubMed ID: 14502226
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of antitumor effect of adenovirus-mediated CD suicide gene therapy by cotransfer of interleukin 2 gene in melanoma-bearing mice.
Ju DW; Cao X; Tao Q; Wang B; Chen G; Yu Y
Chin Med J (Engl); 1999 Feb; 112(2):162-5. PubMed ID: 11593586
[TBL] [Abstract][Full Text] [Related]
9. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10.
Lu XL; Jiang XB; Liu RE; Zhang SM
Vaccine; 2008 Oct; 26(42):5352-7. PubMed ID: 18723067
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model.
Lee CH; Wu CL; Shiau AL
Cancer Gene Ther; 2005 Feb; 12(2):175-84. PubMed ID: 15375381
[TBL] [Abstract][Full Text] [Related]
11. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice.
Kucerova L; Matuskova M; Pastorakova A; Tyciakova S; Jakubikova J; Bohovic R; Altanerova V; Altaner C
J Gene Med; 2008 Oct; 10(10):1071-82. PubMed ID: 18671316
[TBL] [Abstract][Full Text] [Related]
12. Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours.
Jazowiecka-Rakus J; Jarosz M; Szala S
Acta Biochim Pol; 2006; 53(1):199-202. PubMed ID: 16388313
[TBL] [Abstract][Full Text] [Related]
13. [Intratumor injection of recombinant attenuated salmonella carrying Mycobacterium tuberculosis heat shock protein 70 and herpes simplex virus thymidine kinase genes to suppress murine melanoma growth].
Zeng S; Liu Q; Wang S; Peng X; Zhang J; Zhang J
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jan; 32(1):101-5. PubMed ID: 22366015
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
King I; Itterson M; Bermudes D
Methods Mol Biol; 2009; 542():649-59. PubMed ID: 19565926
[TBL] [Abstract][Full Text] [Related]
15. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model.
Souberbielle BE; Westby M; Ganz S; Kayaga J; Mendes R; Morrow WJ; Dalgleish AG
Gene Ther; 1998 Nov; 5(11):1447-54. PubMed ID: 9930297
[TBL] [Abstract][Full Text] [Related]
16. Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice.
Mitrus I; Delić K; Wróbel N; Missol-Kolka E; Szala S
Acta Biochim Pol; 2006; 53(2):357-60. PubMed ID: 16733559
[TBL] [Abstract][Full Text] [Related]
17. Antitumor therapeutic effects of Salmonella typhimurium containing Flt3 Ligand expression plasmids in melanoma-bearing mouse.
Yoon WS; Choi WC; Sin JI; Park YK
Biotechnol Lett; 2007 Apr; 29(4):511-6. PubMed ID: 17235489
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors.
Fu W; Lan H; Li S; Han X; Gao T; Ren D
Cancer Gene Ther; 2008 Jul; 15(7):474-84. PubMed ID: 18437183
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific therapeutic effect induced by an oncolytic adenoviral vector containing heat shock protein 70 and prodrug activation genes.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Gene Ther; 2006 Aug; 13(16):1235-43. PubMed ID: 16617300
[TBL] [Abstract][Full Text] [Related]
20. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma.
Agorio C; Schreiber F; Sheppard M; Mastroeni P; Fernandez M; Martinez MA; Chabalgoity JA
J Gene Med; 2007 May; 9(5):416-23. PubMed ID: 17410612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]